How Sympathetic and Parasympathetic Nerves Work Together in Gastric Cancer Development

0
0
0

How Sympathetic and Parasympathetic Nerves Work Together in Gastric Cancer Development

Gastric cancer (GC) remains one of the most common and deadly cancers worldwide, but new research is highlighting an unexpected driver of its growth: the autonomic nervous system. This system—composed of the sympathetic (“fight-or-flight”) and parasympathetic (“rest-and-digest”) nerves—does more than regulate digestion; it may also tip the balance between healthy and cancerous cells in the stomach.

Jing Gao and Shu-Gang Liu from the Traditional Chinese Medicine Department at The Fourth Hospital of Hebei Medical University in China recently explored how these two nerve systems interact—through both antagonism and coordination—to shape GC development. Their work, published in the Chinese Medical Journal, offers fresh insights into why some tumors grow and spread, and how therapies might target this balance.

The Vagus Nerve: A Parasympathetic Promoter of GC

The parasympathetic system’s star player in GC is the vagus nerve, which controls “rest-and-digest” functions. It’s densely concentrated in the lesser curvature of the stomach (the inner, concave curve)—a region with a significantly higher GC incidence than the outer, convex greater curvature.

Animal studies confirm this link: when mice underwent vagotomy (surgical cutting of the vagus nerve), gastric tumor rates plummeted. In one experiment, 86% of mice with a sham surgery (no nerve cut) developed tumors, compared to just 17% of mice that had their vagus nerves removed. Even partial vagotomy worked: cutting only the anterior vagus nerve reduced anterior stomach tumors to 14% (vs. 76% in the posterior stomach, where the nerve remained intact).

The vagus nerve’s power comes from acetylcholine (ACh), a chemical messenger. Both external ACh (from the nerve) and ACh produced by GC cells themselves (via an enzyme called choline acetyltransferase, or ChAT) fuel cancer growth. This happens through the M3 muscarinic receptor (M3R), which activates cell proliferation pathways like ERK and AKT—key drivers of tumor expansion.

But there’s a check on this process: cholinesterase (CHE), an enzyme that breaks down ACh. Higher CHE levels slow GC growth by reducing the amount of ACh available to stimulate cancer cells.

The Sympathetic Nervous System: A Protective Force (When Healthy)

While the vagus nerve promotes GC, the sympathetic (“fight-or-flight”) system acts as a brake—if it’s functioning properly. In healthy gastric tissue, sympathetic nerve fibers wrap tightly around small arteries. But in GC samples, these fibers are dramatically reduced—especially in tumors that have spread to lymph nodes.

Human data backs this up:

  • In 82 GC surgical specimens, sympathetic nerve fibers were nearly absent in tumors with lymph node invasion.
  • Advanced GC (stage pT4, where cancer has spread through the stomach wall) had far lower sympathetic nerve density than early-stage (pT1–3) tumors.
  • Sympathetic receptors (beta-adrenergic receptors) also shift: beta-1 receptors decrease as lymph node spread increases, while beta-2 receptors are more common in well-differentiated (less aggressive) GC.

The takeaway? A strong sympathetic nervous system may protect against GC—while a weakened one (fewer nerves, fewer active receptors) lets cancer grow.

Gastrin: The Hormone That Ties Nerves to GC Inhibition

Another critical piece of the puzzle is gastrin, a hormone that stimulates stomach acid and digestion. Gao and Liu’s work found gastrin inhibits GC progression—but only when its levels are high.

Here’s how nerves control gastrin:

  1. Blocking the vagus nerve (which normally suppresses gastrin) raises gastrin levels.
  2. Activating the sympathetic system (via beta-2 adrenergic receptors) also boosts gastrin secretion.

When both happen—vagus inhibition + sympathetic activation—gastrin rises, and GC growth slows. This is a key example of how the two nerve systems coordinate to affect cancer.

Estrogen: Why Women Have Lower GC Risk (And How It Links to Sympathetic Nerves)

Globally, women have a much lower GC risk than men—and estrogen may be the reason. Research shows women who use estrogen replacement therapy for over 3 years have a 60% lower GC risk than those who don’t.

Estrogen’s anti-cancer effect ties back to the sympathetic nervous system:

  • Low estrogen activates a receptor called ERα36, which stimulates tumor growth.
  • High estrogen shuts down ERα36 and promotes sympathetic nerve growth (by regulating proteins like neurotrimin).
  • Missing estrogen receptor beta (ERβ) in GC tissues is linked to worse survival.

In short: estrogen strengthens the sympathetic nervous system, which in turn inhibits GC. When estrogen levels drop (e.g., after menopause), the sympathetic system weakens—and GC risk rises.

The Big Picture: Balance Matters Most

Gao and Liu’s findings tell a clear story: GC doesn’t develop from a single “bad” nerve or hormone—it’s about the balance between sympathetic and parasympathetic activity.

A “pro-cancer” state emerges when:

  • The vagus nerve is overactive (too much ACh, too much M3R signaling).
  • The sympathetic system is weakened (fewer nerve fibers, fewer beta receptors).
  • Estrogen levels are low (reducing sympathetic support).
  • Gastrin levels are low (removing a key GC inhibitor).

Conversely, a “protective” state happens when the sympathetic system is strong, the vagus is calm, gastrin is high, and estrogen is balanced.

What This Means for GC Treatment

The study’s biggest takeaway? Treating GC may require looking beyond chemotherapy or surgery to target the autonomic nervous system as a whole. Traditional Chinese medicine (TCM), which emphasizes whole-body balance (yin-yang), may have an advantage here—since it often addresses nerve and hormone harmony alongside tumor growth.

For patients, this research also highlights the importance of factors that support sympathetic health: managing stress (which overactivates the sympathetic system in unhealthy ways), maintaining hormone balance (especially for women), and supporting digestion (to keep gastrin levels in check).

The study was supported by a Special Project of Academician Workstation Construction at The Fourth Hospital of Hebei Medical University. The authors declare no conflicts of interest.

For more details, see the original research and references below:

  1. Zahalka AH, Frenette PS. Nerves in cancer. Nat Rev Cancer 2020;20:143–157. doi: doi.org/10.1038/s41568-019-0237-2
  2. Zhang X, Zhang Y, He Z, et al. Chronic stress promotes gastric cancer progression and metastasis: An essential role for ADRB2. Cell Death Dis 2019;10:788. doi: doi.org/10.1038/s41419-019-2030-2
  3. Wang L, Xu J, Xia Y, et al. Muscarinic acetylcholine receptor 3 mediates vagus nerve-induced gastric cancer. Oncogenesis 2018;7:88. doi: doi.org/10.1038/s41389-018-0099-6
  4. Zhao CM, Hayakawa Y, Kodama Y, et al. Denervation suppresses gastric tumorigenesis. Sci Transl Med 2014;6:250ra115. doi: doi.org/10.1126/scitranslmed.3009569
  5. Yu H, Xia H, Tang Q, et al. Acetylcholine acts through M3 muscarinic receptor to activate the EGFR signaling and promotes gastric cancer cell proliferation. Sci Rep 2017;7:40802. doi: doi.org/10.1038/srep40802
  6. Xu H, Shen Z, Xiao J, et al. Acetylcholinesterase overexpression mediated by oncolytic adenovirus exhibited potent anti-tumor effect. BMC Cancer 2014;14:668. doi: doi.org/10.1186/1471-2407-14-668
  7. Miyato H, Kitayama J, Ishigami H, et al. Loss of sympathetic nerve fibers around intratumoral arterioles reflects malignant potential of gastric cancer. Ann Surg Oncol 2011;18:2281–2288. doi: doi.org/10.1245/s10434-011-1562-1
  8. Bae GE, Kim HS, Won KY, et al. Lower sympathetic nervous system density and beta-adrenoreceptor expression are involved in gastric cancer progression. Anticancer Res 2019;39:231–236. doi: doi.org/10.21873/anticanres.13102
  9. Zu LD, Peng XC, Zeng Z, et al. Gastrin inhibits gastric cancer progression through activating the ERK-P65-miR23a/27a/24 axis. J Exp Clin Cancer Res 2018;37:115. doi: doi.org/10.1186/s13046-018-0782-7
  10. Fossmark R, Rao S, Mjones P, et al. PAI-1 deficiency increases the trophic effects of hypergastrinemia in the gastric corpus mucosa. Peptides 2016;79:83–94. doi: doi.org/10.1016/j.peptides.2016.03.016
  11. Nomura T, Fukudo S, Muranaka M, et al. Impact of stress on serum gastrin in Zollinger-Ellison syndrome. Am J Gastroenterol 1993;88:1432–1435.
  12. Wang Z, Butler LM, Wu AH, et al. Reproductive factors, hormone use and gastric cancer risk: The Singapore Chinese Health Study. Int J Cancer 2016;138:2837–2845. doi: doi.org/10.1002/ijc.30024
  13. Ur Rahman MS, Cao J. Estrogen receptors in gastric cancer: Advances and perspectives. World J Gastroenterol 2016;22:2475–2482. doi: doi.org/10.3748/wjg.v22.i8.2475
  14. Krizsan-Agbas D, Pedchenko T, Smith PG. Neurotrimin is an estrogen-regulated determinant of peripheral sympathetic innervation. J Neurosci Res 2008;86:3086–3095. doi: doi.org/10.1002/jnr.21768

Was this helpful?

0 / 0